tiprankstipranks
Trending News
More News >

Marinus Pharmaceuticals downgraded to Hold from Buy at TD Cowen

TD Cowen analyst Joseph Thome downgraded Marinus Pharmaceuticals (MRNS) to Hold from Buy without a price target after the Phase III trial of ganaxolone in tuberous sclerosis complex failed to meet the primary endpoint. The firm cites the company’s given cash constraints and unclear timing on next steps for the downgrade.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue